Unnamed: 0,title,date,stock,sentiment
208661.0,Calithera Biosciences To Present Telaglenastat KEAPSAKE Trial In Progress Poster At ASCO,2020-05-29 08:37:00-04:00,CALA,positive
208662.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,CALA,neutral
208663.0,"HC Wainwright & Co. Reiterates Buy on Calithera Biosciences, Raises Price Target to $9.5",2020-05-08 07:16:00-04:00,CALA,neutral
208664.0,Calithera Biosciences Q1 EPS $(0.380) Misses $(0.360) Estimate,2020-05-07 16:58:00-04:00,CALA,negative
208665.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,CALA,negative
208666.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CALA,neutral
208667.0,Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial In Progress Abstract Accepted For Presentation At ASCO20 Virtual Annual Meeting,2020-04-30 07:04:00-04:00,CALA,positive
208668.0,Calithera Biosciences Announces The Closing Of its Previously Announced Public Offering Of 5.750 Million Shares Of Common Stock,2020-04-20 16:06:00-04:00,CALA,positive
208669.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,CALA,neutral
208670.0,Mid-Afternoon Market Update: Rite Aid Falls On Wider Q4 Loss; ThermoGenesis Shares Gain,2020-04-16 14:31:00-04:00,CALA,positive
208671.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:58:00-04:00,CALA,neutral
208672.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:57:00-04:00,CALA,neutral
208673.0,Mid-Day Market Update: NASDAQ Jumps 1.8%; Edison Nation Shares Spike Higher,2020-04-16 12:30:00-04:00,CALA,positive
208674.0,Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Misses Q1 Expectations,2020-04-16 10:13:00-04:00,CALA,negative
208675.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,CALA,neutral
208676.0,33 Stocks Moving in Thursday's Pre-Market Session,2020-04-16 07:19:00-04:00,CALA,neutral
208677.0,Calithera Biosciences Prices 5M Share Offering @ $6.25/Share,2020-04-16 05:44:00-04:00,CALA,positive
208678.0,70 Biggest Movers From Yesterday,2020-04-16 04:38:00-04:00,CALA,neutral
208679.0,Calithera Biosciences shares are trading lower after the company announced the commencement of an underwritten public offering of common stock. No size was disclosed.,2020-04-15 16:16:00-04:00,CALA,negative
208680.0,Calithera Biosciences Announces Commencement of Underwritten Public Offering of Common Stock; No Size Disclosed,2020-04-15 16:05:00-04:00,CALA,negative
208681.0,"Cramer Gives His Opinion On Exxon, Polaris And More",2020-04-10 08:40:00-04:00,CALA,neutral
208682.0,80 Biggest Movers From Yesterday,2020-04-08 04:12:00-04:00,CALA,neutral
208683.0,"Citigroup Maintains Buy on Calithera Biosciences, Lowers Price Target to $7",2020-03-27 08:31:00-04:00,CALA,negative
208684.0,"Jefferies Initiates Coverage On Calithera Biosciences with Buy Rating, Announces $6 Price Target",2020-03-27 05:30:00-04:00,CALA,neutral
208685.0,136 Biggest Movers From Yesterday,2020-03-13 05:20:00-04:00,CALA,neutral
208686.0,90 Stocks Moving In Thursday's Mid-Day Session,2020-03-12 12:21:00-04:00,CALA,neutral
208687.0,Calithera Biosciences Q4 EPS $(0.39) Misses $(0.37) Estimate,2020-03-11 16:11:00-04:00,CALA,negative
208688.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,CALA,positive
208689.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,CALA,negative
208690.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,CALA,negative
208691.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,CALA,negative
208692.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,CALA,neutral
208693.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,CALA,neutral
208694.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,CALA,negative
208695.0,Calithera Biosciences Expects to Use $75M to $85M of Cash in 2020,2020-01-13 07:25:00-05:00,CALA,neutral
208696.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,CALA,neutral
208697.0,Calithera Biosciences 13G Filing From PrimeCap Mgmt. Shows New 15% Stake,2020-01-10 11:36:00-05:00,CALA,neutral
208698.0,64 Biggest Movers From Yesterday,2020-01-10 04:58:00-05:00,CALA,neutral
208699.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,CALA,neutral
208700.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-23 12:19:00-05:00,CALA,neutral
208701.0,60 Biggest Movers From Friday,2019-12-23 05:37:00-05:00,CALA,neutral
208702.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,CALA,positive
208703.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,CALA,neutral
208704.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,CALA,neutral
208705.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-11-19 12:45:00-05:00,CALA,neutral
208706.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2019",2019-11-19 09:57:00-05:00,CALA,positive
208707.0,"H.C. Wainwright Initiates Coverage On Calithera Biosciences with Buy Rating, Announces $7 Price Target",2019-11-19 07:48:00-05:00,CALA,neutral
208708.0,81 Biggest Movers From Yesterday,2019-11-14 05:20:00-05:00,CALA,neutral
208709.0,Calithera Biosciences Q3 EPS $(0.38) Beats $(0.45) Estimate,2019-11-12 16:37:00-05:00,CALA,neutral
208710.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,CALA,neutral
208711.0,58 Biggest Movers From Friday,2019-11-04 07:12:00-05:00,CALA,neutral
208712.0,50 Stocks Moving In Friday's Mid-Day Session,2019-11-01 13:09:00-04:00,CALA,neutral
208713.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,CALA,neutral
208714.0,"Calithera Reports Completed Patient Enrollment In CANTATA Trial Of Telaglenastat, Cabozantinib In Advanced Renal Cell Carcinoma",2019-10-03 07:16:00-04:00,CALA,positive
208715.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-02 08:54:00-04:00,CALA,neutral
208716.0,52 Biggest Movers From Yesterday,2019-10-02 04:22:00-04:00,CALA,neutral
208717.0,Calithera Reports Acceptance Of 2 Abstracts From Presentation At SITC Meeting,2019-10-01 16:14:00-04:00,CALA,positive
208718.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,CALA,negative
208719.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,CALA,neutral
208720.0,31 Stocks Moving In Monday's Mid-Day Session,2019-09-30 13:13:00-04:00,CALA,neutral
208721.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,CALA,negative
208722.0,24 Stocks Moving in Monday's Pre-Market Session,2019-09-30 08:41:00-04:00,CALA,neutral
208723.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,CALA,positive
208724.0,Calithera Biosciences Announces Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma at ESMO 2019,2019-09-28 17:28:00-04:00,CALA,positive
208725.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,CALA,positive
208726.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,CALA,positive
208727.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-25 11:56:00-04:00,CALA,negative
208728.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,CALA,neutral
208729.0,Calithera Biosciences Highlights Presentation Of New Data On 2 Oncology Programs At ESMO Congress,2019-09-03 09:21:00-04:00,CALA,neutral
208730.0,Calithera Biosciences Q2 EPS $(0.58) Misses $(0.56) Estimate,2019-08-08 16:51:00-04:00,CALA,negative
208731.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,CALA,neutral
208732.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,CALA,neutral
208733.0,45 Stocks Moving In Monday's Mid-Day Session,2019-08-05 12:37:00-04:00,CALA,neutral
208734.0,Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat In Combination With Pfizer's CDK4/6 Inhibitor Palbociclib,2019-07-02 08:00:00-04:00,CALA,negative
208735.0,55 Biggest Movers From Yesterday,2019-06-20 04:55:00-04:00,CALA,neutral
208736.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-06-19 12:23:00-04:00,CALA,neutral
208737.0,36 Stocks Moving In Wednesday's Pre-Market Session,2019-06-19 08:17:00-04:00,CALA,neutral
208738.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,CALA,positive
208739.0,48 Biggest Movers From Yesterday,2019-06-19 04:50:00-04:00,CALA,neutral
208740.0,Calithera Biosciences Prices 12.5M Share Offering of Common Stock @$4.00/Share,2019-06-19 04:34:00-04:00,CALA,positive
208741.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-06-18 12:39:00-04:00,CALA,neutral
208742.0,Calithera Biosciences shares are trading lower after the company reported a common stock offering of 10 million shares.,2019-06-18 10:30:00-04:00,CALA,positive
208743.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-06-18 08:29:00-04:00,CALA,neutral
208744.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,CALA,neutral
208745.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,CALA,neutral
208746.0,5 Stocks Moving In Monday's After-Hours Session,2019-06-17 16:47:00-04:00,CALA,neutral
208747.0,Calithera Biosciences shares are trading lower after the company reported a common stock offering of 10 million shares.,2019-06-17 16:12:00-04:00,CALA,positive
208748.0,Calithera Biosciences Reports 10M Share Common Stock Offering,2019-06-17 16:03:00-04:00,CALA,positive
208749.0,44 Stocks Moving In Monday's Mid-Day Session,2019-06-17 12:23:00-04:00,CALA,neutral
208750.0,Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy,2019-06-17 10:04:00-04:00,CALA,negative
208751.0,Calithera Biosciences shares are trading higher after the company announced its phase 2 ENTRATA study showed Telaglenastat with Everolimus doubled median progression-free survival in heavily pre-treated patients with advanced renal cell carcinoma.,2019-06-17 08:19:00-04:00,CALA,positive
208752.0,28 Stocks Moving In Monday's Pre-Market Session,2019-06-17 08:06:00-04:00,CALA,neutral
208753.0,Calithera Biosciences Announces 'Positive' Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma,2019-06-17 06:17:00-04:00,CALA,neutral
208754.0,"Citi Assumes Calithera Biosciences at Buy, Announces $10 Price Target",2019-05-30 09:29:00-04:00,CALA,neutral
208755.0,"Calithera Biosciences, Inc. Q1 EPS $(0.61) Misses $(0.44) Estimate",2019-05-09 16:59:00-04:00,CALA,negative
208756.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,CALA,neutral
208757.0,Calithera Biosciences Highlights Presentation Of New Preclinical Data For CB-708 at AACR Annual Meeting 2019,2019-04-02 07:26:00-04:00,CALA,neutral
208758.0,Calithera Reports Initiated Phase 1/2 Trial Of Telaglenastat In Combo With Talazoparib,2019-03-26 07:13:00-04:00,CALA,neutral
208759.0,70 Biggest Movers From Friday,2019-03-11 05:26:00-04:00,CALA,neutral
208760.0,50 Stocks Moving In Friday's Mid-Day Session,2019-03-08 12:31:00-05:00,CALA,neutral
208761.0,"Calithera Biosciences, Inc. Q4 EPS $(0.51) Misses $(0.49) Estimate",2019-03-07 16:27:00-05:00,CALA,negative
208762.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,CALA,negative
208763.0,Calithera Biosciences Initiates Phase 1 Trial Of Arginase Inhibitor CB-280 For The Treatment Of Cystic Fibrosis,2019-02-21 17:15:00-05:00,CALA,negative
208764.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,CALA,neutral
208765.0,Calithera Biosciences Completes Enrollment in its Phase 2 ENTRATA Trial,2019-02-04 07:09:00-05:00,CALA,neutral
208766.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,CALA,neutral
208767.0,"Calithera Biosciences, Inc. - Common Stock Q3 EPS $(0.52) Misses $(0.40) Estimate",2018-11-07 17:21:00-05:00,CALA,negative
208768.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,CALA,negative
208769.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,CALA,neutral
208770.0,"Calithera Biosciences Reports Trial Collaboration To Evaluate IBRANCE, Talazoparib In Combo With CB-839",2018-10-05 07:01:00-04:00,CALA,neutral
208771.0,85 Biggest Movers From Yesterday,2018-08-09 05:15:00-04:00,CALA,neutral
208772.0,"Calithera Biosciences, Inc. - Common Stock Q2 EPS $(0.09) Beats $(0.32) Estimate, Sales $17.06M Beat $6.13M Estimate",2018-08-07 16:15:00-04:00,CALA,neutral
208773.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,CALA,negative
208774.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,CALA,negative
208775.0,"Stocks Which Set New 52-Week Low Friday, July 27",2018-07-30 12:17:00-04:00,CALA,negative
208776.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,CALA,neutral
208777.0,"Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111",2018-06-13 07:48:00-04:00,CALA,negative
208778.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,CALA,negative
208779.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,CALA,positive
208780.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,CALA,positive
208781.0,"Calithera Biosciences Q1 EPS $(0.37) Misses $(0.32) Estimate, Sales $5.189M Miss $7.19M Estimate",2018-05-10 17:19:00-04:00,CALA,negative
208782.0,Calithera Biosciences Announces it Will Present CB-839 Abstracts at ASCO 2018,2018-04-25 16:46:00-04:00,CALA,neutral
208783.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-04-18 12:35:00-04:00,CALA,neutral
208784.0,Calithera Biosciences Shares Up 2.8% After FDA Earlier Granted Fast Track Designation Its CB-839 Treatment,2018-04-18 11:47:00-04:00,CALA,positive
208785.0,24 Stocks Moving In Wednesday's Pre-Market Session,2018-04-18 08:02:00-04:00,CALA,neutral
208786.0,Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma,2018-04-18 07:02:00-04:00,CALA,positive
208787.0,46 Biggest Movers From Yesterday,2018-03-13 05:38:00-04:00,CALA,neutral
208788.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,CALA,neutral
208789.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,CALA,neutral
208790.0,"Calithera Sees Cash, Cash Equivalents, Investments $105M-$115M At End Of '18",2018-03-08 16:49:00-05:00,CALA,neutral
208791.0,"Calithera Biosciences Reports Q4 EPS $(0.31) vs $(0.22) Est., Sales $7.254M vs $5.5M Est., Comps Up 1.3%",2018-03-08 16:49:00-05:00,CALA,neutral
208792.0,45 Biggest Movers From Friday,2018-02-20 04:50:00-05:00,CALA,neutral
208793.0,Calithera Biosciences Shares Up 20% On Earlier Upgrade From Citi,2018-02-16 13:14:00-05:00,CALA,positive
208794.0,36 Stocks Moving In Friday's Mid-Day Session,2018-02-16 12:25:00-05:00,CALA,neutral
208795.0,Citigroup Upgrades Calithera Biosciences to Buy,2018-02-16 09:09:00-05:00,CALA,neutral
208796.0,32 Stocks Moving In Friday's Pre-Market Session,2018-02-16 08:05:00-05:00,CALA,neutral
208797.0,UPDATE: Calithera Says Randomized placebo controlled CANTATA Phase 2 trial of CB-839 in combination with Cabozantinib to begin Q2'18,2018-02-05 17:05:00-05:00,CALA,neutral
208798.0,"Calithera Biosciences Offers Results From Phase 1 Study Of CB-839 In Combo With Everolimus, Cabozantinib In Patients With Renal Cell Carinoma: Overall response rate of 40% and 100% disease control rate",2018-02-05 17:04:00-05:00,CALA,neutral
208799.0,25 Stocks Moving In Friday's Pre-Market Session,2017-11-24 08:05:00-05:00,CALA,neutral
208800.0,31 Stocks Moving In Friday's Pre-Market Session,2017-11-17 08:13:00-05:00,CALA,neutral
208801.0,46 Biggest Movers From Yesterday,2017-11-15 05:04:00-05:00,CALA,neutral
208802.0,34 Biggest Movers From Yesterday,2017-11-14 05:52:00-05:00,CALA,neutral
208803.0,28 Stocks Moving In Monday's Mid-Day Session,2017-11-13 12:47:00-05:00,CALA,neutral
208804.0,Calithera Biosciences To Offer Initial Results From Phase 2 Study Of CB-839 In Combo With Opdivo At SITC Meeting: 'Achieved confirmed responses in melanoma patients progressing on PD-1/PD-L1 therapy',2017-11-07 08:45:00-05:00,CALA,neutral
208805.0,"Calithera Biosciences Reports Q3 EPS $(0.17) vs $(0.22) Est., Sales $7.2M vs $4.5M Est.",2017-11-02 07:45:00-04:00,CALA,neutral
208806.0,Calithera Biosciences Reports First Patient Treated In Phase 1 Cohort Of INCB01158 Dosed In Combo With Keytruda,2017-10-19 08:01:00-04:00,CALA,neutral
208807.0,William Blair Initiates Coverage On Calithera Biosciences with Outperform Rating,2017-10-05 10:11:00-04:00,CALA,neutral
208808.0,Calithera Biosciences Reports CB-839 In Combo With Nivolumab Phase 1/2 Data Accepted For Oral Presentation At SITC Meeting,2017-09-19 15:12:00-04:00,CALA,positive
208809.0,18 Biggest Mid-Day Gainers For Friday,2017-08-11 12:17:00-04:00,CALA,neutral
208810.0,22 Stocks Moving In Friday's Pre-Market Session,2017-08-11 08:23:00-04:00,CALA,neutral
208811.0,"Calithera Biosciences Reports Q2 EPS $(0.15) vs $(0.13) Est., Sales $7.3M vs $10.5M Est.",2017-08-08 16:55:00-04:00,CALA,neutral
208812.0,4 Charts For Navigating Murky Markets,2017-07-06 14:31:00-04:00,CALA,neutral
208813.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-07-06 08:27:00-04:00,CALA,neutral
208814.0,12 Biggest Mid-Day Gainers For Wednesday,2017-07-05 13:05:00-04:00,CALA,neutral
208815.0,This Biotech Name Could Be Best In Breed For 2017,2017-06-13 08:46:00-04:00,CALA,positive
208816.0,Calithera Biosciences Sharply Higher After FDA Fast Track Designation,2017-06-07 10:21:00-04:00,CALA,neutral
208817.0,Calithera Biosciences Reports FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma,2017-06-07 06:48:00-04:00,CALA,positive
208818.0,25 Stocks Moving In Monday's Pre-Market Session,2017-06-05 08:07:00-04:00,CALA,neutral
208819.0,"Bristol-Myers Squibb, Calithera Biosciences Expand Collaboration Evaluating Opdivo in Combination with CB-839 into NSCLC, Melanoma",2017-05-10 07:12:00-04:00,CALA,positive
208820.0,"Calithera Biosciences Reports Q1 EPS $(0.22) vs $(0.52) In Prior Year Period, Sales 4.19M",2017-05-09 16:08:00-04:00,CALA,neutral
208821.0,"H.C. Wainwright Maintains Buy On Calithera Biosciences, Raises Price Target To $14",2017-03-28 07:13:00-04:00,CALA,neutral
208822.0,Calithera Biosciences Drops to Low of $9.65 on Volume; Earlier Priced Offering of 6.83M Common Shares at $10.25/Share,2017-03-22 11:38:00-04:00,CALA,neutral
208823.0,8-K from Calithera Biosciences Shows Offering of 6.83M Common Shares at $10.25/Share,2017-03-22 06:13:00-04:00,CALA,positive
208824.0,Calithera Biosciences Reports Commencement of 4.5M Share Common Stock Offering,2017-03-20 16:02:00-04:00,CALA,positive
208825.0,"Calithera Biosciences Reports Q4 EPS $(0.45) vs $(0.48) Est.; Sees Cash, Cash Equivalents, Investments Between $95M-$105M at End of '17",2017-03-16 16:25:00-04:00,CALA,neutral
208826.0,"Several Biotherapeutics Stocks Outperforming: Cerulean Pharma Up 44%, Adaptimmune 16%, Aurinia 15%, Versatem 14.5%, Heat Biologics 14%, Calithera 14%",2017-03-13 10:54:00-04:00,CALA,neutral
208827.0,Hawkes Bay Master Reports 5.28% Passive Stake In Calithera Biosciences,2017-03-06 12:21:00-05:00,CALA,positive
208828.0,Calithera Biosciences Adds To Wednesday's Gain,2017-03-02 12:59:00-05:00,CALA,positive
208829.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-03-01 08:19:00-05:00,CALA,neutral
208830.0,Calithera Biosciences Spikes to High of $9.60 on Volume,2017-02-17 12:11:00-05:00,CALA,neutral
208831.0,25 Stocks Moving In Friday's Pre-Market Session,2017-02-03 08:12:00-05:00,CALA,neutral
208832.0,Mid-Afternoon Market Update: Tempur Sealy Drops After Loss Of Mattress Firm Contract; Digital Ally Shares Surge,2017-01-30 14:30:00-05:00,CALA,neutral
208833.0,15 Biggest Mid-Day Gainers For Monday,2017-01-30 12:23:00-05:00,CALA,neutral
208834.0,Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher,2017-01-30 12:06:00-05:00,CALA,positive
208835.0,Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates,2017-01-30 10:09:00-05:00,CALA,negative
208836.0,25 Stocks Moving In Monday's Pre-Market Session,2017-01-30 08:28:00-05:00,CALA,neutral
208837.0,"Incyte, Calithera Biosciences Report Global Collaboration for Development, Commercialization of CB-1158",2017-01-30 06:49:00-05:00,CALA,neutral
208838.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2017",2017-01-24 09:23:00-05:00,CALA,positive
208839.0,Citigroup Upgrades Calithera Biosciences To Neutral,2017-01-24 07:36:00-05:00,CALA,neutral
208840.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 14:42:00-05:00,CALA,negative
208841.0,12 Biggest Mid-Day Gainers For Wednesday,2016-12-21 12:42:00-05:00,CALA,neutral
208842.0,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 09:57:00-05:00,CALA,negative
208843.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,CALA,neutral
208844.0,Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo in Combination with CB-839 in Clear Cell Renal Cell Carcinoma,2016-12-21 06:59:00-05:00,CALA,positive
208845.0,Calithera Biosciences Announces Resignation of CFO,2016-12-12 07:03:00-05:00,CALA,negative
208846.0,Calithera Biosciences Halted On Circuit Breaker,2016-12-07 09:50:00-05:00,CALA,neutral
208847.0,Calithera Reports Data On CB-839 Phase I Combination Trial,2016-12-06 09:03:00-05:00,CALA,neutral
208848.0,18 Biggest Mid-Day Gainers For Thursday,2016-11-10 13:09:00-05:00,CALA,neutral
208849.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-11-10 08:28:00-05:00,CALA,neutral
208850.0,Calithera Biosciences Reports Q3 EPS $(0.44) vs. Est. $(0.54),2016-11-09 17:02:00-05:00,CALA,neutral
208851.0,15 Biggest Mid-Day Losers For Tuesday,2016-10-25 13:01:00-04:00,CALA,negative
208852.0,Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts,2016-10-25 12:01:00-04:00,CALA,negative
208853.0,Stocks Hitting 52-Week Lows,2016-10-25 10:31:00-04:00,CALA,negative
208854.0,Benzinga's Top Initiations,2016-10-25 09:32:00-04:00,CALA,positive
208855.0,18 Stocks Moving In Tuesday's Pre-Market Session,2016-10-25 08:27:00-04:00,CALA,neutral
208856.0,"Citigroup Initiates Coverage On Calithera Biosciences, Inc. - Common Stock at Sell, Announces $1.00",2016-10-25 06:09:00-04:00,CALA,neutral
208857.0,Calithera Reports Initial Patient Dosed in a Phase I Study of CB-1158,2016-09-15 07:46:00-04:00,CALA,neutral
208858.0,Calithera Biosciences Reports Q2 Loss/Share ($0.55) vs Est Loss/Share ($0.52),2016-08-09 17:15:00-04:00,CALA,neutral
208859.0,Calithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator,2016-08-04 08:45:00-04:00,CALA,neutral
208860.0,Calithera Reports CB-839 Phase I Solid Tumor Combo Data at ASCO,2016-06-06 07:31:00-04:00,CALA,negative
208861.0,Calithera Biosciences Reports Q1 EPS $(0.52) Vs Est $(0.47),2016-05-10 16:55:00-04:00,CALA,neutral
208862.0,"Calithera Reports Q4 EPS $(0.44) vs $(0.56) Est.; Sees Cash, Cash Equivalents, Investments At Least $35M at End of '16",2016-03-15 07:32:00-04:00,CALA,neutral
208863.0,Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at #ASH2015,2015-12-06 19:17:00-05:00,CALA,neutral
208864.0,Calithera Biosciences Reports Q3 EPS $(0.49) vs $(0.52) Est.,2015-11-09 17:07:00-05:00,CALA,neutral
208865.0,BZ NOTE: Shares of Calithera Were Halted on Circuit Breaker to the Downside; Stock Currently Down ~23%,2015-11-09 10:08:00-05:00,CALA,positive
208866.0,Calithera Biosciences Shares Falling,2015-11-09 10:06:00-05:00,CALA,positive
208867.0,Calithera to Announce New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at  AACR-NCI-EORTC Conference,2015-11-08 16:59:00-05:00,CALA,negative
208868.0,"Calithera Biosciences Appoints Sunil Agarwal, M.D., to Its Board of Directors",2015-09-30 09:08:00-04:00,CALA,neutral
208869.0,Calithera Biosciences Reports Q2 Loss $0.44 Vs Est Loss $0.45,2015-08-10 16:04:00-04:00,CALA,negative
208870.0,"Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora",2015-07-24 13:28:00-04:00,CALA,negative
208871.0,Benzinga's Top Initiations,2015-07-24 09:40:00-04:00,CALA,positive
208872.0,"Citigroup Initiates Coverage on Calithera Biosciences at Buy, Announces $11.00 PT",2015-07-24 07:19:00-04:00,CALA,neutral
208873.0,Calithera Biosciences Announces Selected Immuno-Oncology Clinical Candidate CB-1158 for Treatment of Cancer,2015-06-23 07:02:00-04:00,CALA,negative
208874.0,Watch These 10 After-Hours Movers Today,2015-06-23 06:59:00-04:00,CALA,neutral
208875.0,Morning Market Gainers,2015-06-12 09:49:00-04:00,CALA,neutral
208876.0,Benzinga's Top #PreMarket Gainers,2015-06-12 08:20:00-04:00,CALA,positive
208877.0,Calithera Biosciences Announces Phase I Data for CB-839 in Patients With Acute Leukemias at the 20th Congress of the European Hematology Association,2015-06-11 16:08:00-04:00,CALA,neutral
208878.0,Calithera Reports Positive Phase I Data for CB-839 in Patients with Solid Tumors at ASCO,2015-05-30 09:21:00-04:00,CALA,positive
208879.0,Morning Market Gainers,2015-05-21 09:49:00-04:00,CALA,neutral
208880.0,US Stock Futures Edge Lower Ahead Of Economic Data,2015-05-21 07:58:00-04:00,CALA,negative
208881.0,Calithera Offers Initial Phase I Data for CB-839 in Patients with Acute Leukemias,2015-05-21 07:10:00-04:00,CALA,neutral
208882.0,Calithera Announces Initial Phase I Data for CB-839 in Patients with Acute Leukemias,2015-05-21 07:01:00-04:00,CALA,neutral
208883.0,Watch These After-Hours Movers,2015-05-20 09:16:00-04:00,CALA,neutral
208884.0,Watch These After-Hours Movers Today,2015-05-14 07:16:00-04:00,CALA,neutral
208885.0,Calithera Biosciences Offers Clinical Data Presentation at ASCO '15,2015-04-22 09:02:00-04:00,CALA,neutral
208886.0,Calithera Biosciences Highlights Results From Six Preclinical Abstracts,2015-04-21 07:49:00-04:00,CALA,neutral
208887.0,5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-03-30 09:28:00-04:00,CALA,positive
208888.0,Benzinga's Volume Movers,2015-03-24 10:12:00-04:00,CALA,neutral
208889.0,Benzinga's Volume Movers,2015-03-23 10:40:00-04:00,CALA,neutral
208890.0,Benzinga's Volume Movers,2015-03-06 10:31:00-05:00,CALA,neutral
208891.0,Morning Market Gainers,2015-03-06 09:44:00-05:00,CALA,neutral
208892.0,Benzinga's Top #PreMarket Gainers,2015-03-06 08:07:00-05:00,CALA,positive
208893.0,"After-Hours Movers Led By Calithera Biosciences, Violin Memory & PowerSecure",2015-03-05 17:49:00-05:00,CALA,neutral
208894.0,TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program,2015-03-05 16:05:00-05:00,CALA,positive
208895.0,5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-02-20 09:36:00-05:00,CALA,positive
208896.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2015-02-03 04:32:00-05:00,CALA,negative
208897.0,5 Healthcare Stocks With The Highest EPS,2015-01-20 09:24:00-05:00,CALA,neutral
208898.0,5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-01-09 09:19:00-05:00,CALA,positive
208899.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,CALA,positive
208900.0,Morning Market Movers,2014-12-15 09:44:00-05:00,CALA,neutral
208901.0,Benzinga's Top #PreMarket Gainers,2014-12-15 08:07:00-05:00,CALA,positive
208902.0,"Calithera Biosciences Up 180% For Week On Drug Data, License Pact",2014-12-13 11:37:00-05:00,CALA,neutral
208903.0,"Mid-Day Gainers From December 11: Lululemon, Office Depot, Calithera Biosciences, Heritage Financial",2014-12-11 13:32:00-05:00,CALA,neutral
208904.0,Calithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839,2014-12-10 13:08:00-05:00,CALA,negative
208905.0,"8-K from Calithera Biosciences Shows Co. Will Pay Symbioscience an Upfront, Potential License Payment of $24.7M for First Licensed, Eligible for Added $95M in Royalty Payments",2014-12-09 16:15:00-05:00,CALA,negative
208906.0,"Calithera Biosciences Gains Exclusive, Worldwide License To Mars Symbioscience's Arginase Inhibitors",2014-12-09 09:07:00-05:00,CALA,positive
208907.0,"Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences, Cempra, Isis Pharmaceuticals",2014-12-08 13:00:00-05:00,CALA,neutral
208908.0,Calithera Presents Preclinical Study Findings For CB-839 at 56th American Society Of Hematology Annual Meeting,2014-12-08 12:01:00-05:00,CALA,neutral
208909.0,Calithera Biosciences Appoints H. Ward Wolff To Board of Directors,2014-12-02 17:00:00-05:00,CALA,neutral
208910.0,"Citigroup Initiates Coverage on Calithera Biosciences at Buy, Announces $15.00 PT",2014-10-27 08:36:00-04:00,CALA,neutral
208911.0,"JMP Securities Initiates Coverage on Calithera Biosciences at Market Outperform, Announces $20.00 PT",2014-10-27 08:26:00-04:00,CALA,positive
208912.0,Wells Fargo Initiates Coverage on Calithera Biosciences at Outperform,2014-10-27 06:24:00-04:00,CALA,positive
208913.0,"Leerink Swann Initiates Coverage on Calithera Biosciences at Outperform, Announces $13.00 PT",2014-10-27 06:24:00-04:00,CALA,neutral
208914.0,"Adage Capital Partners Reports 15.47% Passive Stake in Calithera Biosciences as of October 1, 2014",2014-10-22 16:43:00-04:00,CALA,positive
208915.0,"Calithera Biosciences Shares Open for Trade at $10.22/Share, IPO Priced at $10",2014-10-02 10:28:00-04:00,CALA,positive
208916.0,Expected IPOs For October 2,2014-10-02 09:14:00-04:00,CALA,neutral
208917.0,Calithera Biosciences Prices IPO of 8M Shares at $10/Share,2014-10-02 08:09:00-04:00,CALA,positive
208918.0,Calithera Biosciences Prices IPO - 8M shares At $10/share,2014-10-02 08:08:00-04:00,CALA,positive
208919.0,Calithera Biosciences Expects 6M Share IPO to Price $13.00-$15.00/Share,2014-09-19 06:15:00-04:00,CALA,positive
208920.0,"S-1 from Calithera Biosciences Shows $80M IPO, Will List on NASDAQ Under Ticker 'CALA'",2014-08-25 17:31:00-04:00,CALA,neutral
